Theravance Biopharma Inc. (NASDAQ:TBPH) shares are tumbling on Tuesday following the company’s Phase 3 CYPRESS study did not meet its primary endpoint.This disappointing news comes as broader markets are experiencing declines, with major indices such as the S&P 500 and Nasdaq both down. • Theravance Biopharma shares are sliding. What’s pressuring TBPH stock?Pivotal Trial FailureThe CYPRESS study evaluated ampreloxetine for neurogenic orthostatic hypotension due to multiple system atrophy, but the results fe ...